BR112023014337A8 - Anticorpos anti-pdgf-b e métodos de uso para tratar hipertensão arterial pulmonar (pah) - Google Patents
Anticorpos anti-pdgf-b e métodos de uso para tratar hipertensão arterial pulmonar (pah)Info
- Publication number
- BR112023014337A8 BR112023014337A8 BR112023014337A BR112023014337A BR112023014337A8 BR 112023014337 A8 BR112023014337 A8 BR 112023014337A8 BR 112023014337 A BR112023014337 A BR 112023014337A BR 112023014337 A BR112023014337 A BR 112023014337A BR 112023014337 A8 BR112023014337 A8 BR 112023014337A8
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- pah
- pdgf
- methods
- arterial hypertension
- Prior art date
Links
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 230000000702 anti-platelet effect Effects 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
anticorpos anti-pdgf-b e métodos de uso para tratar hipertensão arterial pulmonar (pah). a presente invenção refere-se a anticorpos antissubunidade b do fator de crescimento derivado de plaquetas (pdgf-b) e fragmentos de ligação ao antígeno dos mesmos, bem como métodos de uso de tais anticorpos, ou fragmentos de ligação ao antígeno dos mesmos, para tratar um indivíduo com hipertensão arterial pulmonar (pah).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163141030P | 2021-01-25 | 2021-01-25 | |
PCT/US2022/013666 WO2022159875A1 (en) | 2021-01-25 | 2022-01-25 | Anti-pdgf-b antibodies and mehods of use for treating pulmonary arterial hypertension (pah) |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112023014337A2 BR112023014337A2 (pt) | 2023-09-26 |
BR112023014337A8 true BR112023014337A8 (pt) | 2024-03-05 |
Family
ID=80446637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023014337A BR112023014337A8 (pt) | 2021-01-25 | 2022-01-25 | Anticorpos anti-pdgf-b e métodos de uso para tratar hipertensão arterial pulmonar (pah) |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220242943A1 (pt) |
EP (1) | EP4281475A1 (pt) |
JP (1) | JP2024505195A (pt) |
KR (1) | KR20230135627A (pt) |
CN (1) | CN116964088A (pt) |
AU (1) | AU2022210475A1 (pt) |
BR (1) | BR112023014337A8 (pt) |
CA (1) | CA3205846A1 (pt) |
CO (1) | CO2023010900A2 (pt) |
IL (1) | IL304505A (pt) |
WO (1) | WO2022159875A1 (pt) |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2437213A1 (fr) | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US6573096B1 (en) | 2000-04-01 | 2003-06-03 | The Research Foundation At State University Of New York | Compositions and methods for inhibition of cancer invasion and angiogenesis |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
US7411046B2 (en) | 2005-08-02 | 2008-08-12 | Arius Research Inc | Cancerous disease modifying antibodies |
US8258256B2 (en) | 2006-01-05 | 2012-09-04 | The Johns Hopkins University | Compositions and methods for the treatment of cancer |
US7420041B2 (en) | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
CA2891005A1 (en) | 2007-09-28 | 2008-10-09 | Bind Therapeutics, Inc. | Cancer cell targeting using nanoparticles |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
JP2015536339A (ja) * | 2012-11-09 | 2015-12-21 | ファイザー・インク | 血小板由来増殖因子b特異的抗体ならびにこれらの組成物および使用 |
JP6946184B2 (ja) * | 2014-11-10 | 2021-10-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 抗pdgf−b抗体及び使用法 |
-
2022
- 2022-01-25 US US17/583,930 patent/US20220242943A1/en active Pending
- 2022-01-25 JP JP2023544526A patent/JP2024505195A/ja active Pending
- 2022-01-25 KR KR1020237028422A patent/KR20230135627A/ko unknown
- 2022-01-25 BR BR112023014337A patent/BR112023014337A8/pt unknown
- 2022-01-25 AU AU2022210475A patent/AU2022210475A1/en active Pending
- 2022-01-25 WO PCT/US2022/013666 patent/WO2022159875A1/en active Application Filing
- 2022-01-25 EP EP22704144.9A patent/EP4281475A1/en active Pending
- 2022-01-25 CA CA3205846A patent/CA3205846A1/en active Pending
- 2022-01-25 CN CN202280017601.6A patent/CN116964088A/zh active Pending
-
2023
- 2023-07-17 IL IL304505A patent/IL304505A/en unknown
- 2023-08-22 CO CONC2023/0010900A patent/CO2023010900A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3205846A1 (en) | 2022-07-28 |
IL304505A (en) | 2023-09-01 |
US20220242943A1 (en) | 2022-08-04 |
CN116964088A (zh) | 2023-10-27 |
WO2022159875A1 (en) | 2022-07-28 |
KR20230135627A (ko) | 2023-09-25 |
EP4281475A1 (en) | 2023-11-29 |
JP2024505195A (ja) | 2024-02-05 |
AU2022210475A1 (en) | 2023-08-10 |
CO2023010900A2 (es) | 2023-08-28 |
BR112023014337A2 (pt) | 2023-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Geraldo et al. | Cytoskeletal dynamics in growth-cone steering | |
PH12021550793A1 (en) | Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments | |
EA201290168A1 (ru) | Растения, обладающие повышенными урожайностными свойствами, и способ создания таких растений | |
AR049723A1 (es) | Sustancias activas para el aumento de la defensa frente a patogenos en plantas y metodos para su deteccion | |
BR112012014925A2 (pt) | compostos promotores de replicação de células beta e métodos de uso dos mesmos | |
Belmondo et al. | The Medicago truncatula MtRbohE gene is activated in arbusculated cells and is involved in root cortex colonization | |
Koenig et al. | The interplay of phloem-mobile signals in plant development and stress response | |
UA85543C2 (ru) | Способ культивирования первичных клеток и амплификации вирусов в условиях безсывороточной среды, композиция и ее применение, и способ лечения или вакцинации животных | |
WO2020198509A3 (en) | Modified oligonucleotides with increased stability | |
BR112022018254A2 (pt) | Anticorpos isolados, ácido nucleico isolado, vetor ou conjunto de vetores, célula hospedeira, métodos para produzir um anticorpo, para tratar um distúrbio e para tratar ag em um paciente, composição e uso de um anticorpo | |
MX2022010471A (es) | Anticuerpos monoclonales especificos para el antigeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por vrsh. | |
WO2007032794A3 (en) | Inhibition of viral gene expression using small interfering rna | |
MX2021007001A (es) | Moleculas inhibidoras de acido nucleico de cadena doble que contienen un tribucle. | |
MX2020010802A (es) | Moleculas inhibidoras de acidos nucleicos de caracter bicatenario modificadas con nucleotidos que aumentan la tm. | |
EA202190474A1 (ru) | Терапия на основе микро-рнк, направленная против lcp-1-позитивных раковых опухолей | |
AU2021269176A8 (en) | Single domain antibodies binding to SARS-CoV-2 spike protein | |
MX2021004022A (es) | Modificacion genetica de enzimas dnasas para elaboracion y terapia. | |
AU2021288648A8 (en) | Conjugate of double-stranded siRNA analogue | |
BR112023014337A2 (pt) | Anticorpos anti-pdgf-b e métodos de uso para tratar hipertensão arterial pulmonar (pah) | |
BR112012033296A2 (pt) | peptídeos reguladores da nodulação de soja e métodos de uso | |
DE60124526D1 (de) | Methode zur identifizierung von helicobacter antigenen | |
WO2005018534A3 (en) | Methods and compositions for rna interference | |
EA201990613A1 (ru) | Антитела против гремлина-1 (grem1) и способы их применения для лечения легочной артериальной гипертензии | |
BR112018071186A2 (pt) | rna, pluralidade de rnas, construto de interferência por rna dirigida por dna, composição, método para inibir a expressão de uma proteína, método para tratar distrofia muscular oculofaríngea e kit | |
Schaeper et al. | A conserved function of the zinc finger transcription factor Sp8/9 in allometric appendage growth in the milkweed bug Oncopeltus fasciatus |